bluebird bio (BLUE)
(Delayed Data from NSDQ)
$1.11 USD
+0.03 (2.78%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $1.11 0.00 (0.00%) 7:02 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
BLUE 1.11 +0.03(2.78%)
Will BLUE be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for BLUE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BLUE
bluebird (BLUE) Tops on Q1 Sales, Zynteglo Progresses Well
Zoetis (ZTS) to Report Q1 Earnings: What's in the Cards?
BLUE: What are Zacks experts saying now?
Zacks Private Portfolio Services
bluebird (BLUE) Underperforms Industry YTD Amid Challenges
bluebird (BLUE) Misses on Q4 Revenues, Provides Portfolio Updates
Earnings Preview: Bluebird Bio (BLUE) Q4 Earnings Expected to Decline
Other News for BLUE
bluebird bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Actinium wins FDA nod to conduct clinical trial for radiotherapy
Commit To Buy bluebird bio At $1, Earn 41.2% Annualized Using Options
bluebird bio Reports Inducement Grant to CFO James Sterling Under Nasdaq Listing Rule 5635(c)(4)
bluebird bio's Flight Through Financial Fog And Fierce Rivals